Sulfatrim

Shigellosis, Nocardiosis, Brucellosis + 12 more
Treatment
17 FDA approvals
20 Active Studies for Sulfatrim

What is Sulfatrim

SulfamethoxazoleThe Generic name of this drug
Treatment SummarySulfamethoxazole is an antibiotic that stops bacteria from growing by interfering with the production of folic acid. It is often prescribed in combination with trimethoprim, which blocks two steps in the production of proteins and nucleic acids that are needed for bacterial growth. Together, these medicines can treat bacterial infections in the urinary, respiratory, and gastrointestinal tracts.
Septra DSis the brand name
Sulfatrim Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Septra DS
Sulfamethoxazole
1973
278

Approved as Treatment by the FDA

Sulfamethoxazole, otherwise known as Septra DS, is approved by the FDA for 17 uses like Brucellosis and Pneumocystis Jirovecii Pneumonia .
Brucellosis
Used to treat Brucellosis in combination with Gentamicin
Pneumocystis Jirovecii Pneumonia
Used to treat Pneumocystis Jirovecii Pneumonia in combination with Trimethoprim
Bronchitis
Used to treat Acute Exacerbation of Chronic Bronchitis (AECB) caused by susceptible bacteria in combination with Trimethoprim
Urinary tract infection
Used to treat Urinary Tract Infection caused by susceptible bacteria in combination with Trimethoprim
susceptible Enteritis infectious caused by Shigella sonnei
Used to treat susceptible Enteritis infectious caused by Shigella sonnei in combination with Trimethoprim
Diarrhea
Used to treat susceptible Travelers' Diarrhea caused by Enterotoxigenic E. Coli (ETEC) Infection in combination with Trimethoprim
Brucellosis
Used to treat Brucellosis in combination with Gentamicin
Shigellosis
Used to treat Dysentery, Bacillary in combination with Trimethoprim
Nocardiosis
Used to treat Nocardiosis in combination with Trimethoprim
susceptible Enteritis infectious caused by Shigella flexneri
Used to treat susceptible Enteritis infectious caused by Shigella flexneri in combination with Trimethoprim
Genus Pneumocystis
Used to treat risk of Pneumocystis jiroveci pneumonia (PCP) in combination with Trimethoprim
Otitis Media
Used to treat Acute Otitis Media caused by susceptible bacteria in combination with Trimethoprim
Pneumonia, Pneumocystis
Used to treat Pneumocystis Jirovecii Pneumonia in combination with Trimethoprim
Immunocompromised
Used to treat Immunocompromised in combination with Trimethoprim
Electrolyte replacement
Used to treat Electrolyte replacement in combination with Trimethoprim
Fluid replacement therapy
Used to treat Fluid replacement therapy in combination with Trimethoprim
Cholera
Used to treat susceptible Cholera in combination with Trimethoprim

Effectiveness

How Sulfatrim Affects PatientsSulfamethoxazole is an antibiotic used in combination with another drug, trimethoprim, to treat bacterial infections. Together, these drugs work to slow down bacterial growth more than either one taken alone. However, sulfamethoxazole can cause allergic reactions and should be stopped if a rash appears. People at risk of folate deficiency should use this drug with caution as it can lead to deficiency. Additionally, those with glucose-6-phosphate dehydrogenase deficiency may experience hemolysis when taking sulfamethoxazole/trimethoprim.
How Sulfatrim works in the bodySulfamethoxazole works by stopping bacteria from producing the folic acid they need for reproduction. It does this by blocking an enzyme that turns PABA, a natural substrate, into the folic acid that bacteria require. When the enzyme is blocked, they can't make the folic acid they need and can't reproduce, which stops them from multiplying. This stops the infection and is known as a bacteriostatic effect.

When to interrupt dosage

The quantity of Sulfatrim is contingent upon the determined disorder, including Urinary tract infection, Pneumocystis Jirovecii Pneumonia and Fluid replacement therapy. The dosage can be located in the table below, in relation to the mode of delivery.
Condition
Dosage
Administration
Shigellosis
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
Immunocompromised
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
Otitis Media
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
Nocardiosis
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
Brucellosis
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
Electrolyte replacement
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
Fluid replacement therapy
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
Pneumonia, Pneumocystis
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
Cholera
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
Diarrhea
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
Genus Pneumocystis
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
Urinary tract infection
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
Bronchitis
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
susceptible Enteritis infectious caused by Shigella sonnei
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous
susceptible Enteritis infectious caused by Shigella flexneri
800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL
, Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Warnings

Sulfatrim has seven contraindications, hence it should not be consumed when dealing with any of the conditions outlined in the following table.Sulfatrim Contraindications
Condition
Risk Level
Notes
Megaloblastic anemia caused by Folate deficiency
Do Not Combine
hepatic damage
Do Not Combine
Purpura, Thrombocytopenic, Idiopathic
Do Not Combine
Pulse Frequency
Do Not Combine
Disease
Do Not Combine
unable to monitor renal function
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Sulfamethoxazole may interact with Pulse Frequency
There are 20 known major drug interactions with Sulfatrim.
Common Sulfatrim Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Sulfamethoxazole.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Sulfamethoxazole.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Sulfamethoxazole.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Sulfamethoxazole.
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Sulfamethoxazole.
Sulfatrim Toxicity & Overdose RiskSulfamethoxazole is toxic to mice and rats in doses of 2300mg/kg and 6200mg/kg, respectively. Overdosing on sulfamethoxazole can cause symptoms such as loss of appetite, abdominal pain, nausea, vomiting, dizziness, headache, drowsiness, and unconsciousness. Other symptoms could include fever, blood in the urine, and the formation of crystals in the urine. More serious effects of an overdose could include changes in the blood or imbalances of electrolytes. Treatment for sulfamethoxazole overdose should involve managing symptoms and monitoring patient lab work for
image of a doctor in a lab doing drug, clinical research

Sulfatrim Novel Uses: Which Conditions Have a Clinical Trial Featuring Sulfatrim?

Currently, 8 active studies are underway to assess the potential of Sulfatrim in treating Immunocompromised Patients, Fluid Replacement Therapy and Infectious Enteritis caused by Shigella sonnei.
Condition
Clinical Trials
Trial Phases
Electrolyte replacement
0 Actively Recruiting
Nocardiosis
0 Actively Recruiting
Fluid replacement therapy
0 Actively Recruiting
Pneumonia, Pneumocystis
1 Actively Recruiting
Phase 3
susceptible Enteritis infectious caused by Shigella flexneri
0 Actively Recruiting
Brucellosis
0 Actively Recruiting
Genus Pneumocystis
0 Actively Recruiting
Otitis Media
0 Actively Recruiting
Diarrhea
14 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1
Urinary tract infection
0 Actively Recruiting
Cholera
0 Actively Recruiting
Bronchitis
0 Actively Recruiting
Immunocompromised
3 Actively Recruiting
Not Applicable, Phase 1
susceptible Enteritis infectious caused by Shigella sonnei
0 Actively Recruiting
Shigellosis
0 Actively Recruiting

Sulfatrim Reviews: What are patients saying about Sulfatrim?

3Patient Review
4/29/2008
Sulfatrim for Infection of the Middle Ear by H. Influenzae Bacteria
I'm not sure if this is appropriate for 8-month-olds.
2.7Patient Review
8/29/2008
Sulfatrim for Middle Ear Infection
My daughter was given this medication because she was allergic to amoxicillian. She had loss of appetite and her I/O was very low while on this med. On the 8th day of taking it, she woke up with a head-to-toe body rash.

Patient Q&A Section about sulfatrim

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What bacteria does Sulfatrim treat?

"-An infection caused by the Vibrio cholerae bacteria can result in typhoid or paratyphoid fever. -An infection of the intestines due to Shigella bacteria can be prevented by exposure to plague. -An infection of the brain or spinal cord caused by Listeria monocytogenes can be prevented by exposure to Brucella bacteria."

Answered by AI

Is Sulfatrim a penicillin?

"Yes, Bactrim DS contains sulfamethoxazole and trimethoprim. It has nothing to do with Penicillin. If you're allergic to Penicillin, it's safe to take Bactrim DS. Bactrim DS is an antibiotic and belongs to a drug class called sulfonamides."

Answered by AI

What is Sulfatrim used to treat?

"This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections, such as middle ear, urine, respiratory, and intestinal infections. It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type)."

Answered by AI

What are the side effects of Sulfatrim?

"The side effects of the medication include nausea, vomiting, loss of appetite, and allergic skin reactions such as rash and hives."

Answered by AI

Clinical Trials for Sulfatrim

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA
While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.
Phase < 1
Waitlist Available
Stanford Digestive Health Clinic (+1 Sites)Sean P Spencer, MD, PhD
Have you considered Sulfatrim clinical trials? We made a collection of clinical trials featuring Sulfatrim, we think they might fit your search criteria.Go to Trials
Have you considered Sulfatrim clinical trials? We made a collection of clinical trials featuring Sulfatrim, we think they might fit your search criteria.Go to Trials
Image of McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) in Montreal, Canada.

Low-Dose Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia

18 - 100
All Sexes
Montreal, Canada
Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX. Reduced treatment doses of TMP-SMX for PJP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg/kg/day of TMP) compared to the standard-of-care (15 mg/kg/day) among patients with PJP for the primary outcome of death, new mechanical ventilation, and change of treatment.
Phase 3
Waitlist Available
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)Emily G McDonald, MD MSc
Have you considered Sulfatrim clinical trials? We made a collection of clinical trials featuring Sulfatrim, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security